Previous Agendas

Agenda
Oral Session 1
Incorporating the c-Myc 5’-UTR sequence impacts CD19 CAR T cell efficacy Lishi Xie, Ph.D University of Chicago
LV20.19 CAR-T in PCNSL and SCNSL Anthony Stillwell, MS Medical College of Wisconsin
Drugging BCL-2 in T cells to enhance anti-tumor cytotoxicity Jocelyn Hsu, BS University of Chicago
IL-7 and IL-15 vs IL-2 for CD20/CD19 CAR-T expansion Md Shaheduzzaman, MS Medical College of Wisconsin
Oral Session 2
TCRs with convergent recombination and somatic mutations persist in ovarian cancer Tomohiro Tate, Ph.D University of Chicago
Identifying tumor-reactive T-cells against solid tumors Imaad Said, BS Medical College of Wisconsin
iNKT cells in GVHD prevention Kelsey Busken, MD, MSc WashU Medicine
Anti-mp53 CD8TCR-therapy and CD4TCR prevents cancer relapse Ching-En Lee, MS University of Chicago
Oral Session 3
PI3K inhibition in CAR-T Alexandra Rojek, MD University of Chicago
Characterising the MR1-T cell axis in mycobacterium Idongesit Ekpo, BS University of Chicago
CD47-CD138 BsAb in MM Maday Galeana Figueroa, MS Medical College of Wisconsin
Mechanisms and impact of bystander killing by CAR T cells Joanna Chorazeczewski, MHS University of Chicago